Our pipeline
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.
Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.
The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.
For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.
Brand names are trademarks either owned by and/or licensed to GSK or associated companies.
This information was updated on 27 April 2022.
For COVID-19 vaccines, GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations.
Download full pipeline in XLSX
XLSX - 24.4KB
Key
- †
- In-licence or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
- Ɨ
- GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
- *
- In a Phase 1/2 study
- 1
- Non-registrational
- 2
- Transition activities underway to enable further progression by partner
- 3
- Approved in Canada
- 4
- GSK has exclusive option to co-develop post Ph2
Pipeline updated 27 April 2022
Key
- †
- In-licence or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
- Ɨ
- GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
- *
- In a Phase 1/2 study
- 1
- Non-registrational
- 2
- Transition activities underway to enable further progression by partner
- 3
- Approved in Canada
- 4
- GSK has exclusive option to co-develop post Ph2
Q4 2021 to Q1 2022
Key
- †
- In-licence or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
- Ɨ
- GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
- *
- In a Phase 1/2 study
- 1
- Non-registrational
- 2
- Transition activities underway to enable further progression by partner
- 3
- Approved in Canada
- 4
- GSK has exclusive option to co-develop post Ph2
No results - Please try with another term
Quick Links
Find out more
-
Our approach to R&D
Our new approach to R&D strengthens our pipeline and delivers next generation medicines that we see bringing the greatest value to patients.
-
How we develop new medicines
Developing a medicine takes many years. However, rapid advances in science and technology are transforming healthcare, improving the probability of success in R&D, and may help accelerate this process.
-
How we develop new vaccines
Our work to research, develop and introduce a new vaccine typically goes through several stages.
-
Trials in people
Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.